News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Two Posters and Two Oral Presentations on NOXXON Pharma AG Compounds at 2012 American Society of Hematology Conference



12/6/2012 10:57:53 AM

BERLIN--(BUSINESS WIRE)--NOXXON Pharma announced its participation at the 54th annual meeting of the American Society of Hematology (ASH) in Atlanta, USA from 8-11 December 2012. Two posters will be presented based on the outcome of two independent Phase I clinical trials which assessed the safety of SpiegelmerĀ® NOX-H94 in a first-in-human study as well as its potential to prevent an inflammation induced drop in serum iron in a human experimental model of endotoxemia. NOX-H94 is a candidate for the treatment of anemia of chronic disease. There will also be two oral presentations on the mode of action of the SpiegelmerĀ® NOX-A12 in two hematological cancers, chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), which were studied in novel experimental settings.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES